FHTX Stock Analysis: Buy, Sell, or Hold?
FHTX - Foghorn Therapeutics Inc. Common Stock
$4.90
0.12 (2.51%)
▲
5d:
-0.61%
30d:
-11.23%
90d:
-4.85%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When FHTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: FHTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: FHTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: FHTX is currently trading at $4.90, which is considered slightly low relative to its 30-day fair value range of $4.81 to $5.66.
Technical Outlook: Technically, FHTX is in a uptrend. Immediate support is located at $4.35, while resistance sits at $5.36.
Market Sentiment: FHTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.44 (+133.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, FHTX is in a uptrend. Immediate support is located at $4.35, while resistance sits at $5.36.
Market Sentiment: FHTX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.44 (+133.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$4.81 -
$5.66
Company Quality Score
39/100
(SELL)
Options IV Signal
25th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 25th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 133.6% below Wall St target ($11.44)
Fair Price Analysis
30-Day Fair Range
$4.81 -
$5.66
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.68
(14.0%)
Support & Resistance Levels
Support Level
$4.35
Resistance Level
$5.36
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.38
Wall Street Target
$11.44
(+133.6%)
Revenue Growth (YoY)
223.8%
Profit Margin
-240.3%
Share & Embed Analysis
Last updated: April 02, 2026 8:59 AM ET
Data refreshes hourly during market hours. Next update: 9:59 AM
Data refreshes hourly during market hours. Next update: 9:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FHTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 45 HOLD |
